Programme (updated March 6)
IOF-ECCEO12 CONGRESS - BORDEAUX 2012
Day 2 - Thursday, March 22
Venue |
 Palais des Congrès de Bordeaux |
|
|---|---|---|
| 9.00 - 11.50 |
Scientific Session I
Chaipersons: T. Bardin - B. Dawson-Hughes - J.A. Kanis |
AMPHI A |
| 9.00 - 9.30 |
Plenary Lecture 1
Changes in epidemiology of osteoporotic fractures - C. Cooper
|
AMPHI A |
| 9.30 - 9.40 |
Presentation of the ESCEO-Amgen Fellowships
|
AMPHI A |
| 9.40 - 9.50 |
Presentation of the Young Investigator Awards
|
AMPHI A |
| 9.50 - 10.20 |
Oral Communications selected from abstracts
|
AMPHI A |
| 10.20 - 10.50 |
Plenary Lecture 2
Is Rheumatoid Arthritis a bone disease? - W.F. Lems
|
AMPHI A |
| 10.50 - 11.50 |
Oral Communications selected from abstracts
|
AMPHI A |
| 12.15 - 13.45 |
Amgen/GSK Lunch Symposium
Approach unmet medical needs in osteoporosis treatment
Chaipersons: R. Rizzoli and R. Chapurlat
• Address the unmet needs in fracture reduction - R. Rizzoli
• How does denosumab contribute to the unmet needs in fracture reduction? - S. Papapoulos
• Tolerability of long term osteoporosis treatment with denosumab - C. Roux
• Discussion - panel
|
AMPHI A |
| 12.15 - 13.45 |
MSD Lunch Symposium
Optimizing osteoporosis management; an evolving science
Chairperson: P. Orcel
• Welcome and opening remarks
• New insights in the effective management of osteoporosis; focus on vitamin D - J.-Y. Reginster
• Odanacatib - An antiresorptive that preserves bone formation - S. Ferrari
• Current and future therapeutic [clinical] strategies for the management of post menopausal OP - P. Orcel
• Panel Discussion and Q&A
|
AMPHI B |
| 14.00 - 15.00 |
Educational Lecture
How bone is built - E. Seeman
|
AMPHI B |
| 13.45 - 15.00 |
Poster Session 1
|
POSTERS |
| 14.00 - 15.00 |
Oral presentation of selected posters
Chair: - E. McCloskey
|
MAIN HALL |
| 14.00 - 15.00 |
Meet-The-Expert Sessions
|
|
|
Efficacy and safety of calcium supplements - S. Boonen
|
ROOM E1 | |
|
Management of osteoarthritis - T. Bardin
|
ROOM E2 | |
|
Sequential therapies - S. Ferrari
|
ROOM F1 | |
|
Sarcopenia and physical frailty: epidemiology and risk factors - A.A. Sayer
|
ROOM F2 | |
| 14.00 - 15.00 |
ESCEO-FIRMO Symposium
Prevention of bone fractures in post-menopausal women treated with aromatase inhibitors for breast cancer
Chaipersons: M. L. Brandi and R. Rizzoli
• Introduction - M. L. Brandi
• The use of aromatase inhibitors for breast cancer in Europe: the present and the future projections - A. De Censi
• Skeletal Effects of aromatase inhibitors: revision of the controlled clinical trials - René Rizzoli
• Guidelines on the management of breast cancer treatment induced bone loss. – J.-J. Body
• Conclusions - R. Rizzoli
|
ROOM D |
| 14.00 - 15.00 |
IOF-ECTS-ESCEO-FROMO Symposium
Chaipersons: J. Compston - R. Adachi - C. Cooper
|
ROOM H |
|
14.00 - 14.30
ESCEO-FROMO: Treatment of glucocorticoïd-induced osteoporosis (GIOP)
• Treatment of GIOP versus PMO: similarities and differences
- A. Diez-Perez • Treatment of GIOP with bisphosphonates and other agents - S. Papapoulos • Discussion |
||
|
14.30 - 15.00
IOF-ECTS: Guidelines for the Management of GIO
• Risk assesment in GIO - E. McCloskey
• IOF-ECTS Guideline - J. Compston
• Close
|
||
|
The panel is constituted by R. Adachi, J. Compston, C. Cooper, W. Dere, J. P. Devogelaer, A. Diez-Perez, J.A. Kanis, A. Laslop, S. Papapoulos, S. Ralston, J.-Y. Reginster, S. Reiter, R. Rizzoli, C. Roux, T. Schaeverbeke, Y. Tsouderos, G. Weryha |
||
| 15.00 - 16.50 |
Scientific Session II
Chaipersons: T. Thomas - E. Seeman - J.P. Devogelaer |
AMPHI A |
| 15.30 - 16.50 |
Oral Communications selected from abstracts
|
AMPHI A | 15.00 - 15.30 |
Plenary Lecture 3
Gender specifity, the male paradigm - E. Orwoll
|
AMPHI A |
| 15.15 - 16.50 |
IOF CNS Scientific Session
Models of care for secondary fracture prevention : the IOF "Capture the Fracture Programme"
Chaipersons: J.-Y. Reginster and J. Stenmark
|
ROOM E |
| 17.00 - 18.30 |
Servier International Satellite Symposium
Structure and fracture: two fundamentals of osteoporosis treatment
Chaipersons: C. Cooper and J.-Y. Reginster
• Introduction - C. Cooper
• The bone structure-strength relation in osteoporosis - D. Felsenberg
• Improvement of the osteoporotic bone structure with strontium ranelate - R. Rizzoli
• New data on strontium ranelate’s antifracture efficacy - C. Cooper
• Panel Discussion - Chair: J.-Y. Reginster
• Conclusion - J.-Y. Reginster
|
AMPHI A |
| 17.00 - 18.30 |
Eli Lilly and Company Satellite Symposium
Osteoporotic fractures: the case for bone forming therapy
Chaiperson: D. Agnusdei
• Improving bone strength with bone forming agents
- A. Diez-Perez • Role of sequential or combination therapy for osteoporosis - M.L. Brandi • Effects of PTH Peptides on bone structure and fracture incidence: the European experience - J. Stepan • Closing Commentary |
AMPHI B |
